Capricor Reports Q1 Loss, Confirms Deramiocel FDA Review & August PDUFA Date

summarizeSummary

Capricor Therapeutics reported a widened net loss for Q1 2026 but confirmed its Deramiocel BLA is under active FDA review with an August 22, 2026 PDUFA date, alongside updates on commercialization efforts and a lawsuit against its distributor.

check_boxKey Events

• Q1 2026 Financial Results

  Capricor reported a widened net loss of $33.9 million ($0.59 per share) for Q1 2026, with no revenue, but maintains a cash balance of $278.6 million, providing a runway into Q4 2027.

• Deramiocel BLA Under Active FDA Review

  The Biologics License Application (BLA) for Deramiocel is under active FDA review, with a PDUFA target action date of August 22, 2026, and labeling discussions expected to commence soon.

• Commercialization Efforts & Leadership

  The company's GMP manufacturing facility is operational with expansion underway, and a Chief Commercial Officer with direct Duchenne Muscular Dystrophy (DMD) commercial experience is set to join.

• Lawsuit Against Distributor

  Capricor reiterated its May 7th lawsuit against NS Pharma, seeking to rescind the U.S. distribution agreement due to a flawed pricing structure and unmet commercial obligations, noting FDA review is unaffected.

auto_awesomeAnalysis

This 8-K provides the official Q1 2026 financial results, showing a widened net loss and increased operating expenses, though the company maintains a strong cash position and runway into Q4 2027. More importantly, it offers a comprehensive corporate update on the critical Deramiocel program, including the ongoing FDA review with a PDUFA target action date of August 22, 2026, and progress in manufacturing and commercial team building. The filing also reiterates the previously announced lawsuit against NS Pharma, which aims to resolve a distribution agreement issue impacting patient access. The potential for a Priority Review Voucher upon approval is a significant non-dilutive capital opportunity.